Initial Data from Investigator-Initiated Ph 2 Trial of ZYNLONTA® in Patients with R/R MZL Announced May 14, 2024
Calquence combo regimen demonstrated statistically significant and clinically meaningful PFS improvement in 1L MCL in ECHO Ph 3 trial May 7, 2024
Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with R/R EBV+ PTCL Announced April 16, 2024
Enrollment in Part 2 dose expansion initiated in LOTIS-7 Trial of ZYNLONTA® + Glofitamab or Mosunetuzumab in Patients with R/R B-cell NHL April 9, 2024
Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML published in Leukemia & Lymphoma April 8, 2024
Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy Announced April 2, 2024
Enrollment Completed for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with R/R PCNSL March 26, 2024
Lacutamab monotherapy development in PTCL to be discontinued after the anti-KIR3DL2 antibody fell short in Ph Ib trial March 26, 2024
FDA issued CRLs for the BLAs for odronextamab in R/R follicular lymphoma (FL) and in R/R DLBCL, each after two or more lines of systemic therapy March 26, 2024
FDA Accepts BLA Resubmission Of LYMPHIR™ (Denileukin Diftitox) For The Treatment Of Adults With R/R Cutaneous T-Cell Lymphoma March 26, 2024
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy March 18, 2024
Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Ph 1 study for R/R Follicular Lymphoma March 18, 2024
AvantGen Receives Milestone Payment for First Patient Dosed in Ph 1 Study with Kite’s CAR-T Therapy March 12, 2024
Kite Receives U.S. FDA Approval Of Manufacturing Process Change to Reduce Median Turnaround Time For Yescarta March 4, 2024
FDA Accepts for Priority Review the Supplemental BLA for Epcoritamab (EPKINLY®) for Difficult-to-Treat R/R Follicular Lymphoma March 4, 2024
